Tg Therapeutics (TGTX) Net Income towards Common Stockholders Growth (1y) (2012 - 2026)
Tg Therapeutics (TGTX) Net Income towards Common Stockholders Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 116.57% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Tg Therapeutics | 8.08 Bn | 8.00 Bn | 171.41 Mn | 289.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 289.96% |
| Dec 31, 2025 | -25.35% |
| Sep 30, 2025 | 10,005.87% |
| Jun 30, 2025 | 311.43% |
| Mar 31, 2025 | 147.33% |
| Dec 31, 2024 | 335.54% |
| Sep 30, 2024 | -96.60% |
| Jun 30, 2024 | 114.39% |
| Mar 31, 2024 | 72.71% |
| Dec 31, 2023 | 84.10% |
| Sep 30, 2023 | 378.13% |
| Jun 30, 2023 | 15.33% |
| Mar 31, 2023 | 47.78% |
| Dec 31, 2022 | 12.58% |
| Sep 30, 2022 | 60.30% |
| Jun 30, 2022 | 33.33% |
| Mar 31, 2022 | 18.34% |
| Dec 31, 2021 | -9.17% |
| Sep 30, 2021 | 99.80% |
| Jun 30, 2021 | 99.75% |